Preventing Cirrhosis with Oral Therapy: The Potential Impact of Seladelpar in PBC

This chapter explores Seladelpar, an oral therapy aimed at preventing end stage liver disease and cirrhosis in patients with primary biliary cholangitis (PBC). It discusses how the therapy works, its benefits in improving liver tests and quality of life, and the importance of offering simple oral therapies to patients.